LQDA
Liquidia Corporation
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2018-07-26
$42.20
+0.35 (+0.84%)
last quote
Want the full multi-source brief on LQDA?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$42.20
High
$43.37
Low
$41.58
Previous close
$41.85
Fundamentals
Market cap
$3.78B
P/E (TTM)
27.25x
P/S (TTM)
8.38x
P/B
12.93x
Gross margin
92.56%
Operating margin
37.39%
Net margin
30.74%
Rev growth (YoY)
2233.65%
EPS growth (YoY)
—
ROE
149.64%
52W high
$93.61
52W low
$22.21
Beta
0.41x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-10in 5 daysbefore market
Q3 2026EPS est $0.98Rev est $218.5M
Recent SEC filings
CIK 1819576filing-language history →
Recent news
2026-10-28 → 2026-11-04
ChartMill · 2h
Liquidia Corp (NASDAQ:LQDA) Offers Affordable Growth With Strong Revenue and Reasonable Forward Valuation
Liquidia (LQDA) scores 6/10 in Affordable Growth: strong 8/10 growth, fair forward valuation, solid health, but risks remain.
Yahoo · 23h
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. East
Yahoo · 5d
Why Did Insmed Stock Jump?
For questions about this article or underlying research, email help@trefis.com.
Yahoo · 5d
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 5d
What Is Behind Liquidia's Lead Over Its Industry?
For questions about this article or underlying research, email help@trefis.com.
Yahoo · 6d
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Yahoo · 6d
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial